Loading clinical trials...
Loading clinical trials...
Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane
Conditions
Interventions
Everolimus
Letrozole
Locations
7
Israel
Novartis Investigative Site
Jerusalem, Israel
Novartis Investigative Site
Kfar Saba, Israel
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Rehovot, Israel
Novartis Investigative Site
Tel Aviv, Israel
Start Date
August 9, 2011
Primary Completion Date
November 20, 2012
Completion Date
April 30, 2017
Last Updated
March 26, 2021
NCT06625775
NCT06649331
NCT04862663
NCT05894239
NCT06557148
NCT07053085
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions